NCT04396912

Brief Summary

In the present study, the severity of recurrent laryngeal nerve injury (RLNI) and hypocalcemia (H) will be followed-up and the probable interrelation between them will be proposed considering the clinical situation of patients, e.g. improvement in hypocalcemia also make a positive effect on voice? (any objective sign? Ca? PTH?), return of voice is parallel with the improvement in hypocalcemia? Postoperative calcium (Ca), parathyroid hormone (PTH), regular vocal cord evaluations by ear-nose-throat (ENT) exams, deterioration-stability-improvement of clinical symptoms regarding both Ca metabolism and vocal cord function will be noted at regular intervals (postoperative day 1-3-first, weekly control/first month, monthly/first 6-month, 3-monthly/6-12 months) at outpatient controls. Serum Ca, PTH, ENT evaluation of vocal cords-noted.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started May 2020

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 15, 2020

Completed
Same day until next milestone

Study Start

First participant enrolled

May 15, 2020

Completed
6 days until next milestone

First Posted

Study publicly available on registry

May 21, 2020

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2021

Completed
Last Updated

May 21, 2020

Status Verified

May 1, 2020

Enrollment Period

1 year

First QC Date

May 15, 2020

Last Update Submit

May 15, 2020

Conditions

Keywords

Total thyroidectomy

Outcome Measures

Primary Outcomes (4)

  • s/p TT- normal (no complication)

    TT: total thyroidectomy

    June 01, 2020-June 01, 2021

  • s/p TT+VCP

    VCP: vocal cord paralysis

    June 01, 2020-June 01, 2021

  • s/p TT+H

    H: hypocalcemia

    June 01, 2020-June 01, 2021

  • s/p TT+VCP+H

    Any improvement recorded? VCP? H? vice versa

    June 01, 2020-June 01, 2021

Secondary Outcomes (1)

  • Improvement in vocal cord function /serum calcium

    June 01, 2020-June 01, 2021

Study Arms (4)

Control, s/p TT, without complication

Control (status/post-s/p total thyroidectomy-TT, without complication- demographics and BMI matched)

Procedure: Total thyroidectomy

Experimental, s/p TT with only VCP

Experimental (s/p TT, with only vocal cord paralysis-VCP, uni or bilateral)

Procedure: Total thyroidectomy

Experimental, s/p TT with only H

Experimental (s/p TT, with only hypocalcemia-H, transient or permanent)

Procedure: Total thyroidectomy

Experimental, s/p TT with both VCP+H

Experimental (s/p TT, with both vocal cord paralysis-VCP and hypocalcemia-H); Subgroups: 4.1. VCP (Permanent) + H (Permanent) 4.2. VCP (Transient) + H (Transient) 4.3. VCP (Permanent) + H (Transient) 4.4. VCP (Transient) + H (Permanent) Please answer: * Improvement in hypocalcemia also make a positive effect on voice? (any objective sign? Ca? PTH?) * Return of voice is parallel with the improvement in hypocalcemia? (any objective sign? Ca? PTH?

Procedure: Total thyroidectomy

Interventions

Patients with thyroid diseases either benign (e.g. multinodular goitre) or malign (e.g. thyroid carcinoma) will be prepared for total thyroidectomy procedure and will be enrolled.

Control, s/p TT, without complicationExperimental, s/p TT with both VCP+HExperimental, s/p TT with only HExperimental, s/p TT with only VCP

Eligibility Criteria

Age17 Years+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients with benign or malign thyroid diseases, eligable for total thyroidectomy

You may qualify if:

  • Patients with total thyroidectomy indication, for either benign (e.g. multinodular goitre) or malign (e.g. thyroid carcinoma) thyroid disease
  • \>17 year-old
  • Available for close follow-ups at outpatient clinic
  • Available for close vocal cord exams

You may not qualify if:

  • Patients with recurrent thyroid disease (benign/malign), prepared for a second operation
  • Preferance of thyroid surgery other than total thyroidectomy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Umraniye Education and Research Hospital, Health Sciences University

Istanbul, 34764, Turkey (Türkiye)

RECRUITING

Related Publications (2)

  • Cuschieri S. The STROBE guidelines. Saudi J Anaesth. 2019 Apr;13(Suppl 1):S31-S34. doi: 10.4103/sja.SJA_543_18.

  • Giulea C, Enciu O, Toma EA, Calu V, Miron A. The Tubercle of Zuckerkandl is Associated with Increased Rates of Transient Postoperative Hypocalcemia and Recurrent Laryngeal Nerve Palsy After Total Thyroidectomy. Chirurgia (Bucur). 2019 Sept-Oct;114(5):579-585. doi: 10.21614/chirurgia.114.5.579.

Related Links

MeSH Terms

Conditions

Vocal Cord ParalysisWounds and InjuriesThyroid Cancer, PapillaryThyroid NeoplasmsThyroid Nodule

Condition Hierarchy (Ancestors)

Laryngeal DiseasesRespiratory Tract DiseasesOtorhinolaryngologic DiseasesVagus Nerve DiseasesCranial Nerve DiseasesNervous System DiseasesParalysisNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsAdenocarcinoma, PapillaryAdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsEndocrine Gland NeoplasmsNeoplasms by SiteHead and Neck NeoplasmsEndocrine System DiseasesThyroid Diseases

Study Officials

  • Sema YUKSEKDAG, MD

    Instructor in General Surgery

    PRINCIPAL INVESTIGATOR
  • Ethem UNAL, MD, PhD, USMLE & IFSO-Certified, Board CSS

    Assoc. Professor of General Surgery and Surgical Oncology

    STUDY CHAIR

Central Study Contacts

Ethem UNAL, MD, PhD, USMLE & IFSO-Certified, Board CSS

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD, PhD, USMLE & IFSO-Certified, BCSS, Associated Professor of General Surgery and Surgical Oncology

Study Record Dates

First Submitted

May 15, 2020

First Posted

May 21, 2020

Study Start

May 15, 2020

Primary Completion

June 1, 2021

Study Completion

June 1, 2021

Last Updated

May 21, 2020

Record last verified: 2020-05

Data Sharing

IPD Sharing
Will share

Study is open to high-volume INTERNATIONAL endocrine surgery centers, eager to join to present STROBE compatible observational study Available upon email requests@drethemunal@gmail.com

Shared Documents
STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE
Time Frame
From June 01, 2020, for 6 months
Access Criteria
Contact to drethemunal@gmail.com

Locations